 | |
 | |
| Clinical data | |
|---|---|
| Other names | 4-OH-DBT; 4-Hydroxy-N,N-dibutyltryptamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C18H28N2O |
| Molar mass | 288.435 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 74 to 75 °C (165 to 167 °F) |
| |
| |
 N Y (what is this?) (verify) | |
4-HO-DBT, also known as4-hydroxy-N,N-dibutyltryptamine, is apsychedelic drug of thetryptamine family related topsilocin (4-HO-DMT).[1] It is takenorally.[1]
In his bookTiHKAL (Tryptamines I Have Known and Loved),Alexander Shulgin reported that a 20 mg dose of 4-HO-DBTorally produced no effects.[1] However, this compound has subsequently been sold as a "research chemical" andanecdotal reports suggest that at higher doses 4-HO-DBT is indeed an activehallucinogen, although somewhat weaker than other similar tryptamine derivatives.[citation needed]
4-HO-DBT is found either as itscrystallinehydrochloridesalt or as an oily or crystallinebase.
Thechemical synthesis of 4-HO-DBT has been described.[1]
Several differentisomers of 4-HO-DBT could be made, including 4-HO-DiBT,4-HO-DsBT, and 4-HO-DtBT, but of these only theisobutyl isomer 4-HO-DiBT wassynthesized byAlexander Shulgin (melting point 152 to 154 °C) and was also found to be inactive at a 20 mg dose.[1] Theserotonin receptor interactions of these isomers have been studied.[2]
4-HO-DBT was first described in thescientific literature byDavid Repke and colleagues in 1977.[3] It was subsequently described in further detail byAlexander Shulgin in his 1997 bookTiHKAL (Tryptamines I have Known and Loved).[1]